IRRs from trials of sirolimus and paclitaxel eluting stents and RIRR comparing sirolimus with paclitaxel in patients with diabetes
| Study | IRR (95% confidence interval) | |||
|---|---|---|---|---|
| In-stent restenosis | In-segment restenosis | TLR | MACE | |
| *I2, test of heterogeneity. | ||||
| Sirolimus trials | ||||
| SIRIUS (2003)4 | 0.17 (0.08 to 0.37) | 0.35 (0.20 to 0.62) | 0.31 (0.15 to 0.64) | 0.37 (0.19 to 0.70) |
| E-SIRIUS (2003)1 | 0.13 (0.03 to 0.57) | 0.19 (0.06 to 0.64) | 0.21 (0.05 to 0.91) | 0.27 (0.08 to 0.94) |
| C-SIRIUS (2004)3 | 0.06 (0.003 to 1.02) | 0.13 (0.02 to 1.00) | 1.00 (0.06 to 15.99) | 1.00 (0.06 to 15.99) |
| DIABETES (2005)30 | 0.15 (0.06 to 0.39) | 0.22 (0.10 to 0.47) | 0.24 (0.10 to 0.59) | 0.31 (0.15 to 0.66) |
| RAVEL (2002)2 | 0.06 (0.003 to 0.97) | 0.06 (0.003 to 0.97) | 0.07 (0.004 to 1.19) | 0.22 (0.05 to 0.98) |
| SES-SMART (2004)8 | NA | 0.39 (0.17 to 0.91) | NA | NA |
| Combined IRR | 0.15 (0.09 to 0.25) | 0.28 (0.20 to 0.41) | 0.27 (0.16 to 0.45) | 0.33 (0.21 to 0.51) |
| Heterogeneity* | (0.0%, p = 0.92) | (0.0%, p = 0.59) | (0.0%, p = 0.73) | (0.0%, p = 0.89) |
| Paclitaxel trials | ||||
| TAXUS I (2003)5 | NA | NA | 0 events | 0 events |
| TAXUS II (2003)6, 32, 33 | NA | 0.07 (0.004 to 1.17) | 0.16 (0.02 to 1.25) | NA |
| TAXUS IV (2004)7, 29 | 0.16 (0.05 to 0.48) | 0.18 (0.07 to 0.49) | 0.36 (0.19 to 0.70) | NA |
| TAXUS VI (2005)31 | 0.20 (0.05 to 0.68) | 0.23 (0.08 to 0.66) | 0.20 (0.04 to 0.90) | 0.55 (0.21 to 1.43) |
| Combined IRR | 0.18 (0.08 to 0.40) | 0.19 (0.09 to 0.38) | 0.31 (0.18 to 0.56) | 0.55 (0.21 to 1.43) |
| Heterogeneity* | 0.0%, p = 0.80 | 0.0%, p = 0.73 | 0.0%, p = 0.62 | NA |
| RIRR (sirolimus v paclitaxel) | 0.82 (0.31 to 2.18) p = 0.694 | 1.51 (0.68 to 3.33) p = 0.312 | 0.86 (0.40 to 1.86) p = 0.703 | 0.60 (0.21 to 1.71) p = 0.336 |